About PGDx

Advisors

Kenneth Kinzler, PhD
Kenneth Kinzler, PhD is Professor of Oncology at The Johns Hopkins Kimmel Cancer Center and a member of the National Cancer Institute’s Scientific Advisory Board. According to the Institute for Scientific Information in Philadelphia, Dr. Kinzler is one of the most influential scientists alive today.  He has produced classic studies of the genes causing human cancer including the discovery of APC, the gene that initiates virtually all colorectal tumors.  His subsequent analyses of the functional properties of the APC gene product have had widespread ramifications for developmental biology as well as cancer biology.  He is also internationally renowned for his development of genetic methods for analyzing gene expression and mutations in human cancer.  His work has spawned over 100 patent applications, most focused on the use of genetic approaches to improve the diagnosis and management of patients with cancers and other serious diseases.
Nickolas Papadopoulos, PhD
Dr. Nickolas Papadopoulos is an expert in cancer diagnostics and the development of diagnostic tests. He is known as a co‐discoverer of the genetic basis of the predisposition to hereditary nonpolyposis colon cancer (HNPCC). His discovery that mutations in the mismatch repair genes (MSH2, MLH1, MSH6, and PMS2) predispose to HNPCC had important ramifications for the understanding of cancers with a very high rate of mutations and led to the development of diagnostic tests for the presymptomatic diagnosis of individuals with HNPCC. He was part of the interdisciplinary team that was first to sequence all of the protein coding genes and determine genetic alterations and construct expression profiles in multiple tumors of four different common human cancers. A noteworthy discovery he has made in the recent years is the identification of novel, signature mutations in ovarian clear cell carcinomas and pancreatic neuroendocrine tumors. These mutations are in genes that control epigenetic changes in the cell. Currently, he is focused on translating the genetic information derived from cancer genome analyses to clinical applications in early detection, diagnosis and monitoring of cancer. He is a co-developer of sensitive methods for the detection of tumor DNA in liquid biopsy.
Bert Vogelstein, MD
Bert Vogelstein, MD was the first scientist to elucidate the molecular basis of a common human cancer. In particular, he and his colleagues have demonstrated that colorectal tumors result from the gradual accumulation of genetic alterations in specific oncogenes and tumor suppressor genes. His group's discovery and analysis of these genes and their functions represent a landmark in the application of molecular biology to the study of human disease. His work on colorectal cancers forms the paradigm for much of modern cancer research, with profound implications for diagnostic and therapeutic strategies in the future. According to the Institute for Scientific Information in Philadelphia, Dr. Vogelstein is currently the most highly cited scientist in the world.
Shibin Zhou, MD PhD
Shibin Zhou, MD PhD is Associate Professor of Oncology at Johns Hopkins Kimmel Cancer Center. He is an expert in molecular genetics of cancer and translational medicine, having pioneered novel molecular approaches to cancer therapy. He completed his medical training in internal medicine in China and later on received a PhD in Molecular Biology from the University of Pittsburg. In 1994, he joined the Johns Hopkins Kimmel Cancer Center where he analyzed signal transduction pathways in cancer cells.  Dr. Zhou joined the faculty in 2002 with a focus on translational research.